A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies

Trial Profile

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs LAG 525 (Primary) ; PDR 001 (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 12 Oct 2018 to 28 Apr 2019.
    • 26 Jun 2017 Planned primary completion date changed from 12 Oct 2018 to 28 Apr 2019.
    • 15 Sep 2016 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top